MX2023003216A - Inhibidores de mdm2 para usarse en el tratamiento o prevencion de la reincidencia de neoplasias hematologicas despues del trasplante de celulas hematopoyeticas. - Google Patents

Inhibidores de mdm2 para usarse en el tratamiento o prevencion de la reincidencia de neoplasias hematologicas despues del trasplante de celulas hematopoyeticas.

Info

Publication number
MX2023003216A
MX2023003216A MX2023003216A MX2023003216A MX2023003216A MX 2023003216 A MX2023003216 A MX 2023003216A MX 2023003216 A MX2023003216 A MX 2023003216A MX 2023003216 A MX2023003216 A MX 2023003216A MX 2023003216 A MX2023003216 A MX 2023003216A
Authority
MX
Mexico
Prior art keywords
cell transplantation
relapse
prevention
treatment
hematopoietic cell
Prior art date
Application number
MX2023003216A
Other languages
English (en)
Inventor
Robert Zeiser
Justus Duyster
Hans Dietrich Menssen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023003216A publication Critical patent/MX2023003216A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a un inhibidor de doble minuto de ratón 2 (MDM2, por sus siglas en inglés) para usarse en el tratamiento y/o prevención de una reincidencia de neoplasia hematológica después de un trasplante de células hematopoyéticas (HCT, por sus siglas en inglés) en un paciente. En modalidades, la neoplasia hematológica es una leucemia, preferiblemente leucemia mieloide aguda (AML, por sus siglas en inglés). Preferiblemente, el paciente recibió un trasplante alogénico de células T, ya sea junto con el HCT y/o después del HCT, tal como en el momento de la administración de MDM2. Además, la invención se refiere a una composición farmacéutica que comprende un inhibidor de MDM2 y un inhibidor de exportina 1 (XPO-1) para usarse en el tratamiento y/o prevención de una reincidencia de neoplasia hematológica después de un trasplante de células hematopoyéticas (HCT) en un paciente de acuerdo con cualquiera de las reivindicaciones anteriores.
MX2023003216A 2020-09-21 2021-09-21 Inhibidores de mdm2 para usarse en el tratamiento o prevencion de la reincidencia de neoplasias hematologicas despues del trasplante de celulas hematopoyeticas. MX2023003216A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20197230 2020-09-21
EP21184448 2021-07-08
PCT/EP2021/075896 WO2022058605A1 (en) 2020-09-21 2021-09-21 Mdm2 inhibitors for use in the treatment or prevention of hematologic neoplasm relapse after hematopoietic cell transplantation

Publications (1)

Publication Number Publication Date
MX2023003216A true MX2023003216A (es) 2023-04-14

Family

ID=77914387

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003216A MX2023003216A (es) 2020-09-21 2021-09-21 Inhibidores de mdm2 para usarse en el tratamiento o prevencion de la reincidencia de neoplasias hematologicas despues del trasplante de celulas hematopoyeticas.

Country Status (11)

Country Link
US (1) US20230338374A1 (es)
EP (1) EP4213834A1 (es)
JP (1) JP2023543163A (es)
KR (1) KR20230074195A (es)
AU (1) AU2021346233A1 (es)
BR (1) BR112023001596A2 (es)
CA (1) CA3189973A1 (es)
IL (1) IL301105A (es)
MX (1) MX2023003216A (es)
TW (1) TW202218665A (es)
WO (1) WO2022058605A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981541A4 (en) 2006-01-23 2011-09-28 Errico Joseph P METHODS AND COMPOSITIONS FOR DEVELOPING A TARGET MEDICINE
KR20130027080A (ko) 2010-01-06 2013-03-14 에리코, 조셉, 피. 표적화된 약물 개발 방법 및 조성물
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
JP7332589B2 (ja) 2017-10-12 2023-08-23 ノバルティス アーゲー 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ
CA3050645A1 (en) * 2018-07-27 2020-01-27 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia

Also Published As

Publication number Publication date
KR20230074195A (ko) 2023-05-26
JP2023543163A (ja) 2023-10-13
AU2021346233A1 (en) 2023-03-02
CA3189973A1 (en) 2022-03-24
TW202218665A (zh) 2022-05-16
IL301105A (en) 2023-05-01
BR112023001596A2 (pt) 2023-04-04
EP4213834A1 (en) 2023-07-26
US20230338374A1 (en) 2023-10-26
WO2022058605A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
JOP20220008A1 (ar) مثبطات parp1
MX2021011826A (es) Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2023003216A (es) Inhibidores de mdm2 para usarse en el tratamiento o prevencion de la reincidencia de neoplasias hematologicas despues del trasplante de celulas hematopoyeticas.
EA202290154A1 (ru) Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
WO2022119858A8 (en) Compounds for the treatment of sars
WO2022221528A3 (en) Kras g12c inhibitors
MX2022013867A (es) Combinacion farmaceutica que comprende tno155 y nazartinib.
MX2022010960A (es) Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
MX2023009677A (es) Inhibidores de enzimas.
AU2021300281A8 (en) RORγt inhibitors and topical uses thereof
MX2020010231A (es) Una combinacion farmaceutica triple que comprende dabrafenib, trametinib y un inhibidor de erk.
MX2023006231A (es) Inhibidores de enzimas.
MX2022014303A (es) Compuestos para el tratamiento del sars.
WO2022119854A8 (en) Compounds for the treatment of sars
MX2022010574A (es) Composicion farmaceutica que comprende compuesto derivado de bencimidazol.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.